Urispas 200

Quick links to important sections

Urispas 200

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urispas 200

Quick Facts

Property Description
Active ingredient Flavoxate (as Flavoxate hydrochloride)
Form Oral Tablet (film-coated)
Pharmacological class Urinary Tract Antispasmodic
General purpose Relief of symptoms associated with bladder spasm
Origin Synthetic Compound

Classification and Core Identity of Urispas 200

Urispas 200 is a single-ingredient, prescription-only oral medication containing the active compound Flavoxate. This substance is formally classified as a urinary tract antispasmodic, a category defined by its functional effect on the smooth muscle of the lower urinary system. The product is supplied as an oral tablet, commonly film-coated, for consistent systemic effect when administered. The active compound is the synthetic compound Flavoxate hydrochloride.

Flavoxate: Origin and Antispasmodic Action

The mechanism of Flavoxate is characterized by its musculotropic antispasmodic properties, initiating smooth muscle relaxation directly within the bladder wall. This direct action targets and diminishes excessive, involuntary muscle contractions, or spasms. This distinction establishes that the medication's purpose is to manage symptoms related to functional muscle hypercontractility rather than addressing microbiological infection. The general purpose of this therapy is to provide symptomatic relief by helping to lessen disruptive sensations such as sudden, critical urinary urgency and abnormal frequency of urination (frequency), which are common signs of bladder spasm.

What side effects are possible with Urispas 200?

Possible Side Effects and Safety Information

The safety profile for Urispas 200 (Flavoxate) is detailed in official regulatory documentation, outlining potential adverse reactions and use restrictions. Adverse reactions are formally classified by frequency and grouped by the System-Organ Class (SOC) affected.

Classification Examples of Documented Adverse Reactions
Common Nausea
Uncommon Somnolence, Visual impairment, Dry mouth, Vomiting, Dyspepsia, Rash
Rare Urinary retention, Urticaria, Fatigue, Pruritus
Not Known Glaucoma, Anaphylactic shock, Jaundice, Mental confusion, Palpitations

Serious adverse reactions, though rare and often with an unknown frequency of occurrence, include anaphylactic shock, hepatic abnormalities (e.g., jaundice or abnormal liver enzymes), and glaucoma. The labeling notes that mental confusion is a documented risk, particularly in the elderly population.

Safety restrictions are explicitly listed in regulatory documents. Flavoxate is contraindicated and must not be used in individuals with pre-existing obstructive conditions, including pyloric or duodenal obstruction, obstructive uropathies of the lower urinary tract, or conditions such as myasthenia gravis or glaucoma. Caution is required when administering the medicine to patients with suspected glaucoma or renal impairment due to the metabolic clearance of the drug. Furthermore, safety and effectiveness have not been established for children under 12 years of age.

Overdose and Emergency Response

Overexposure to Urispas 200 (Flavoxate) has been officially documented to result in a range of systemic manifestations, primarily affecting the central nervous system (CNS), cardiovascular system, and autonomic function. Documented clinical signs may include severe dizziness, hallucinations, unusual excitement, and mental confusion, with this state being specifically noted in the older adult population. Other presentations include severe drowsiness, clumsiness or unsteadiness, fever, flushing of the face, and changes such as increased heart rate and increased blood pressure.

In any case of suspected overdose, contacting the Poison Control Center is required. Urgent medical attention must be sought immediately when severe, life-threatening outcomes are observed, as stated in official guidance. Call emergency services immediately if overexposure results in a state of collapse, the onset of seizures (convulsions), or if the person has trouble breathing or is unresponsive (cannot be awakened).

Medical management is focused on providing symptomatic and supportive treatment. Official regulatory information does not describe a specific pharmacological antidote for Flavoxate overexposure.

Therapeutic Uses of Urispas 200

What Urispas 200 Treats: Main Uses and Benefits

Urispas 200 (Flavoxate) is relevant for supporting relief of symptomatic discomfort related to muscle spasms in the urinary tract, and is commonly used across conditions characterized by periods of heightened symptoms that lead to noticeable physiological strain. This medication is indicated for the symptomatic relief of distress related to lower urinary tract irritation.


Quick Fact: Relief for Bladder Spasms Property Description
Primary Focus Symptom management of heightened physiological activity
Key Benefit Supports relief of urgency, frequency, and pain
Typical Context Adjunctive use in inflammatory/irritative states

The medication plays a role in managing symptom clusters that may become intense or disruptive, helping to address manifestations of an irritable bladder. It is used for addressing pronounced symptoms such as sudden, compelling urinary urgency, excessive frequency (day and night), and dysuria (painful urination), as may occur in conditions including cystitis, urethritis, or prostatitis. Providing relief in this domain contributes to easing discomfort and may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. FDA Prescribing Information (via DailyMed)

Eligibility and Restrictions for Use

Urispas 200 (flavoxate hydrochloride) is generally prescribed for adults and children over the age of 12 to relieve symptoms of lower urinary tract irritation. Its safety and effectiveness have not been established in children younger than 12 years of age.


Contraindications (Who Should Not Use Urispas 200)

Urispas 200 should not be used in patients with certain pre-existing conditions due to the risk of exacerbating obstruction or other serious effects. Absolute contraindications include:

  • Obstructive Conditions: Patients with obstruction of the pylorus or duodenum, obstructive intestinal lesions, paralytic ileus, or other gastrointestinal obstructive disorders.
  • Gastrointestinal Hemorrhage: Active bleeding from the stomach or intestines.
  • Achalasia: A condition affecting the muscular wall of the esophagus.
  • Obstructive Uropathies: Blockages of the lower urinary tract, such as urinary retention.
  • Glaucoma: Specifically, angle-closure glaucoma, as the drug may increase ocular pressure.
  • Myasthenia Gravis: A neuromuscular disease causing muscle weakness.
  • Hypersensitivity: Known allergy to flavoxate hydrochloride or any other ingredients in the medication.

Use in Specific Populations

Population Recommendation
Pregnancy Use only if clearly needed and the benefit outweighs the potential risk, as there are no adequate studies in pregnant women.
Breastfeeding Use is generally not recommended as it is unknown if the drug is excreted in human milk.
Elderly Use with caution; elderly patients may be more sensitive to side effects like mental confusion or drowsiness.
Renal Impairment Caution is advised, as impaired kidney function may affect how the drug is cleared from the body.

What should I know about interactions with other medicines?

The official interaction profile for Urispas 200 (Flavoxate) is defined by its pharmacodynamic class effects, primarily relating to its action as a urinary tract antispasmodic with anticholinergic-like properties. Regulatory documentation establishes constraints for co-administration, focusing on the potential for additive functional effects.

Interaction Scope Constraint Details (Official Regulatory Information)
Interacting Categories Anticholinergic drugs, Central Nervous System (CNS) depressants, and specific gastric motility inhibitors.
Prohibited Combinations Co-administration with Pramlintide is classified as contraindicated due to the risk of synergistic inhibition of gastrointestinal motility, a severe interaction pattern.
Procedural Requirements For diagnostic purposes, Flavoxate must be discontinued for a minimum of five half-lives prior to the administration of Secretin for stimulation testing. This mandatory separation prevents an incorrect test result (hyporesponse).
Substance Interaction Co-administration with alcohol should be avoided because of the potential for additive CNS depression, which can intensify side effects such as drowsiness and impaired attention.
Population Notes Elderly patients are identified in official labeling as a population with heightened sensitivity to the drug's CNS effects, specifically increasing the risk for the adverse outcome of mental confusion.

The interaction structure is thus built upon mandatory restrictions and prohibitions against combining the product with other substances that share or intensify its functional effects on motility or the CNS. No formal pharmacokinetic interactions involving CYP enzymes or transporters are explicitly detailed in the core regulatory documentation.

Mechanism of Action

Urispas (flavoxate) acts via multiple pharmacological pathways to modulate smooth muscle activity within the urinary tract. Its principal mechanism involves the direct interaction with the detrusor muscle in the bladder wall.

Modulation of Contraction Pathways

Urispas influences the intracellular environment by functioning as an inhibitor of specific phosphodiesterases (PDEs). This enzyme inhibition results in an elevation of intracellular concentrations of cyclic AMP (cAMP). The subsequent cascade decreases the phosphorylation state of myosin, which reduces the contractile state of the smooth muscle fibers.

Secondary Mechanisms

Additionally, the drug displays activity as an antagonist at certain calcium channels. By modulating the influx of calcium ions (Ca^2+) into the cell, Urispas further suppresses the excitation-contraction coupling required for sustained muscle contraction. A third component involves weak antimuscarinic properties, where flavoxate acts as an antagonist at acetylcholine receptors, decreasing neurotransmitter-mediated stimulation. This combined modulation results in reduced smooth muscle tone and altered afferent nerve signaling in the system.

Dosage and Administration Information

How to Use Urispas 200: Administration Guidelines

Urispas 200 (Flavoxate hydrochloride) is administered as an oral tablet for symptomatic relief. Administration includes a specific route, dosage, frequency, and conditions for its use.

Dosage and Frequency

The standard dose established for adults and adolescents is 100 milligrams (mg) to 200 mg per single administration. The medication is taken multiple times daily, typically three or four times a day (TID or QID), to maintain a consistent effect. If a scheduled dose is missed, instructions are to skip the forgotten dose and resume the regular schedule, without taking a double dose to compensate.

Administration Constraints

The tablet must be swallowed whole with water and must not be crushed, broken, or chewed. Regarding food intake, the tablet may be taken with or without food; however, taking the dose after a meal may help mitigate potential nausea.

Population Rules and Titration

The use of Flavoxate is for adults and children over 12 years of age. Use is not established for younger pediatric populations. For patients with renal impairment, caution is required because the kidneys are responsible for the clearance of the active metabolite. The overall duration of use is guided by symptomatic need, and the dosage may be reduced once symptomatic improvement is achieved.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Urispas 200

This section provides a neutral summary of the clinical studies, meta-analyses, and regulatory reports describing the scientific evaluation of Flavoxate, focusing on the study designs and populations examined.


Evidence for Symptom Relief in Lower Urinary Tract Irritation

Research examining Flavoxate was studied for outcomes related to physical discomfort and systemic or functional imbalance in the lower urinary system. The evidence base includes established Randomized Controlled Trials (RCTs) and studies comparing it against a placebo (an inactive pill). These trials were applied in research exploring how symptoms change over time, and they studied short-term symptom changes in adult populations.

Studies monitored patient-reported outcomes describing perceived discomfort linked to inflammatory or irritative states. Researchers explored how symptoms evolved in the observed populations, with a focus on specific measures like urinary frequency, urgency, and dysuria (painful urination). Findings describe patterns observed in the studies. Research highlights changes measured during the study period.


Study Focus on Functional Bladder Outcomes

Beyond patient-reported feelings, research has explored the effects of Flavoxate using objective functional measures. Urodynamic studies were a key component of this research, which examined temporary physiological imbalance. The study outcomes examined in this context included measures like Bladder Volume Capacity (BVC), which reflects how much the bladder can hold during a test.


Evidence in Special Populations and Specific Conditions

Flavoxate was studied for adults presenting with symptoms related to inflammatory or irritative states. The research has also examined its use for symptoms related to Lower Urinary Tract Symptoms (LUTS), which may be associated with conditions like BPH (enlarged prostate).

Evidence for certain groups, however, remains limited. Children over 12 years of age have been included in some evaluations. However, regulatory authorities have noted that data for certain groups remain insufficient, and the safety and evidence of what the drug can do are not fully established for children under 12 years of age.


What Remains Uncertain About the Research Base

The overall evidence for Flavoxate was observed in some studies to have limitations. Some of the existing research, particularly the earlier trials, have sample sizes that were modest. Evidence quality varies across studies.

Long-term effects are not fully established, and research focusing on the sustained maintenance of observed changes is an area where data are still emerging. Certainty remains low in some areas of the research.

Key Studies & References

  1. Flavoxate HCl Tablets 100 mg - Official Prescribing Information (DailyMed)
  2. Flavoxate in the symptomatic treatment of overactive bladder: a meta-analysis
  3. Effect of flavoxate on hyperactive detrusor muscle

Frequently Asked Questions (FAQ)

Common questions about Urispas 200 (FAQ)


Q: Is Urispas 200 an antibiotic, or does it work differently?

A: Urispas 200 (Flavoxate) is not an antibiotic. Official product information states that it is classified as a urinary tract antispasmodic. Its function is described as relaxing the smooth muscles in the urinary tract to relieve symptoms like urgency and pain, and it is not indicated for the treatment of bacterial infections.


Q: How long does it usually take for Urispas 200 to start working?

A: Clinical studies described in official documents indicate that the effect of Urispas 200 typically starts to be noticeable within one hour of administration. The peak concentration of the drug in the body, which relates to its strongest effect, is generally observed around two hours after administration.


Q: Is Urispas 200 the same as other bladder spasm medicines like oxybutynin?

A: While Urispas 200 and medicines like oxybutynin are both used for bladder symptoms, their primary mechanisms of action are different. Urispas 200 works mainly by directly relaxing the bladder muscle while having only weak antimuscarinic properties. Other similar medicines are primarily classified as different types of antimuscarinics.


Q: Can Urispas 200 help with bladder pain (not just frequency)?

A: Official labeling indicates that Urispas 200 is used for the symptomatic relief of suprapubic pain (lower abdominal pain) and dysuria, which is the medical term for painful urination. Therefore, it is officially described for managing specific types of pain associated with lower urinary tract irritation.


Q: How long do the common side effects of Urispas 200, like dry mouth or dizziness, typically last?

A: Official information indicates that common side effects, such as dry mouth or nausea, often resolve on their own with time as the body adjusts to the medication. If these or any other side effects persist or worsen, this information should be discussed with a healthcare provider.


Q: What is the risk of taking Urispas 200 with alcohol?

A: The interaction between Urispas 200 and alcohol is generally classified as a moderate risk. Taking them together may lead to additive nervous system side effects, such as increased dizziness, drowsiness, and difficulty concentrating. Official documentation states that alcohol should be avoided during treatment.


Q: Is Urispas 200 safe to use for people over the age of 65?

A: The drug is used in the elderly population, though caution is advised. Official warnings state that older patients may be more sensitive to the medication, and there is an increased risk of side effects such as mental confusion in this age group.


Q: Is Urispas 200 available as a generic medicine?

A: Yes, the active ingredient, flavoxate hydrochloride, is available as a generic medicine from various manufacturers. The generic version contains the same active ingredient and strength as the brand-name product.


Q: How does Urispas 200 affect sweating or body temperature?

A: Official adverse reaction lists include the possibility of hyperpyrexia (an elevated body temperature or fever), although this is a rare effect. The medication is also associated with increased sensitivity to light, but regulatory documents do not list specific warnings about changes in sweating for this drug.


Q: Is Urispas 200 a habit-forming or addictive medication?

A: According to regulatory status and common drug references, Urispas 200 (Flavoxate) is not classified as a controlled substance. The medication is not known to have a habit-forming or addictive potential.


Q: Are there any specific over-the-counter (OTC) cold or allergy medicines that interact with Urispas 200?

A: Urispas 200 possesses antimuscarinic properties. Taking it alongside other medicines that share this effect, such as certain OTC cold, allergy, or sleep aids, may cause additive side effects. This means side effects like dry mouth or dizziness could become more intense.


Q: What happens if Urispas 200 is stopped suddenly?

A: Flavoxate is not associated with severe or dangerous withdrawal symptoms upon stopping. However, the regulatory information notes that the symptoms the medication was used to treat, such as urinary urgency and frequency, may return once the treatment is discontinued.


Q: What is the difference in how Urispas 200 works compared to an alpha-blocker?

A: Urispas 200 is a urinary antispasmodic that works by relaxing the bladder muscle to reduce spasms. In contrast, alpha-blockers work by relaxing the smooth muscle in the prostate and bladder neck. These different mechanisms mean the medications act on different parts of the lower urinary system.


Q: Is Urispas 200 only for short-term use, or can it be used long-term?

A: The overall duration of treatment with Urispas 200 is typically determined by the patient's symptomatic need. Official documentation notes that the duration of use is guided by symptomatic need. However, it is noted that long-term studies to determine the carcinogenic potential of the drug have not been performed.


Q: What should be avoided while on Urispas 200 to minimize dizziness?

A: Since Urispas 200 can cause dizziness and drowsiness, official guidance states that individuals should avoid consuming alcohol and avoid activities that require high mental alertness, such as driving or operating heavy machinery, until they understand how the drug affects them.


Q: Is Urispas 200 effective for men and women equally?

A: Official documentation does not make a specific distinction regarding the drug's efficacy based on sex. Urispas 200 is indicated for symptoms that can arise from conditions in both men (e.g., prostatitis) and women (e.g., cystitis), and clinical studies were generally conducted on adult subjects.


Q: How quickly does the effect of Urispas 200 wear off?

A: Regulatory documents do not specify a clinical 'duration of effect' or half-life. However, official studies indicate that the active component of the drug is rapidly excreted from the body, with a majority passing in the urine within 24 hours.

How should Urispas 200 be stored and disposed of?

Official Storage and Disposal Requirements

Urispas 200 mg (Flavoxate hydrochloride) must be stored strictly according to regulatory labeling to maintain product stability and ensure safety.

Storage Requirement Specification
Temperature Store below 30 C or at Controlled Room Temperature (20 C to 25 C)
Protection Keep away from excess heat, moisture, and light. The product must not be frozen.
Packaging Store in the original outer carton and keep the tablets in a tight, light-resistant container.
Child Safety Mandatory to keep the medicine out of the sight and reach of children.
Disposal Dispose of unused or expired product according to local regulations, often involving drug take-back programs or specific household trash guidelines. Do not dispose of into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urispas 200 found in:

A-Z Index: